Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy

Therapy related‐acute myeloid leukemia (t‐AML) and myelodysplastic syndrome (t‐MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcinoma who developed autoimmune hemolytic anemia and MDS associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakatsuru, Kousei, Tsubouchi, Kazuya, Hirahata, Minori, Nakashima, Tadayuki, Takahata, Yuriko, Okamatsu, Yuki, Shiraishi, Yoshimasa, Okamoto, Isamu, Harada, Taishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396777/
https://www.ncbi.nlm.nih.gov/pubmed/37337950
http://dx.doi.org/10.1111/1759-7714.15005
_version_ 1785083838120067072
author Nakatsuru, Kousei
Tsubouchi, Kazuya
Hirahata, Minori
Nakashima, Tadayuki
Takahata, Yuriko
Okamatsu, Yuki
Shiraishi, Yoshimasa
Okamoto, Isamu
Harada, Taishi
author_facet Nakatsuru, Kousei
Tsubouchi, Kazuya
Hirahata, Minori
Nakashima, Tadayuki
Takahata, Yuriko
Okamatsu, Yuki
Shiraishi, Yoshimasa
Okamoto, Isamu
Harada, Taishi
author_sort Nakatsuru, Kousei
collection PubMed
description Therapy related‐acute myeloid leukemia (t‐AML) and myelodysplastic syndrome (t‐MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcinoma who developed autoimmune hemolytic anemia and MDS associated with a combination of atezolizumab and platinum‐based chemotherapy. The patient showed progression from t‐MDS to t‐AML 20 months after the treatment was initiated. A combination of immune checkpoint inhibitor (ICI) and chemotherapy may increase the risk of developing therapy‐related myeloid neoplasms. As the prognosis of t‐AML and t‐MDS is poorer than that of de novo AML and MDS, proper surveillance, follow‐up, and treatment are needed throughout the course of immunotherapy.
format Online
Article
Text
id pubmed-10396777
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-103967772023-08-04 Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy Nakatsuru, Kousei Tsubouchi, Kazuya Hirahata, Minori Nakashima, Tadayuki Takahata, Yuriko Okamatsu, Yuki Shiraishi, Yoshimasa Okamoto, Isamu Harada, Taishi Thorac Cancer Case Reports Therapy related‐acute myeloid leukemia (t‐AML) and myelodysplastic syndrome (t‐MDS) are complications of chemotherapy and/or radiation therapy for malignant diseases. In this report, we describe a patient with advanced lung adenocarcinoma who developed autoimmune hemolytic anemia and MDS associated with a combination of atezolizumab and platinum‐based chemotherapy. The patient showed progression from t‐MDS to t‐AML 20 months after the treatment was initiated. A combination of immune checkpoint inhibitor (ICI) and chemotherapy may increase the risk of developing therapy‐related myeloid neoplasms. As the prognosis of t‐AML and t‐MDS is poorer than that of de novo AML and MDS, proper surveillance, follow‐up, and treatment are needed throughout the course of immunotherapy. John Wiley & Sons Australia, Ltd 2023-06-20 /pmc/articles/PMC10396777/ /pubmed/37337950 http://dx.doi.org/10.1111/1759-7714.15005 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Nakatsuru, Kousei
Tsubouchi, Kazuya
Hirahata, Minori
Nakashima, Tadayuki
Takahata, Yuriko
Okamatsu, Yuki
Shiraishi, Yoshimasa
Okamoto, Isamu
Harada, Taishi
Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
title Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
title_full Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
title_fullStr Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
title_full_unstemmed Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
title_short Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
title_sort acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum‐based chemotherapy
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10396777/
https://www.ncbi.nlm.nih.gov/pubmed/37337950
http://dx.doi.org/10.1111/1759-7714.15005
work_keys_str_mv AT nakatsurukousei acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT tsubouchikazuya acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT hirahataminori acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT nakashimatadayuki acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT takahatayuriko acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT okamatsuyuki acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT shiraishiyoshimasa acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT okamotoisamu acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy
AT haradataishi acutemyeloidleukemiaandmyelodysplasticsyndromeassociatedwithacombinationofimmunecheckpointinhibitorandplatinumbasedchemotherapy

Ejemplares similares